

The cross-scale correlations between individuals and nations in COVID-19 mortality

Lei Zhang

Institute of Health System Engineering, College of Engineering, Peking University

Yu-Rong She

Institute of Health System Engineering, College of Engineering, Peking University

Guang-Hui She

Institute of Health System Engineering, College of Engineering, Peking University

Rong Li

Institute of Health System Engineering, College of Engineering, Peking University

Zhen-Su She (✉ she@pku.edu.cn)

Institute of Health System Engineering, College of Engineering, Peking University

Research Article

Keywords:

Posted Date: January 3rd, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1133246/v2>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

1 **The cross-scale correlations between individuals and nations in**
2 **COVID-19 mortality**

3 **Authors**

4 Lei Zhang¹, Yu-Rong She¹, Guang-Hui She¹, Rong Li^{1,2*} and Zhen-Su She^{1,2*}

5 **Affiliations**

6 ¹Institute of Health System Engineering, College of Engineering, Peking University,
7 Beijing, China.

8 ²State Key Laboratory for Turbulence and Complex Systems, Peking University,
9 Beijing, China.

10

11 *Correspondence to she@pku.edu.cn & rongli-coe@pku.edu.cn;

12

13 **Abstract**

14 It is challenging to quantitatively clarify the determining medical and social factors of
15 COVID-19 mortality, which varied by 2-3 orders of magnitude across countries. Here,
16 we present evidence that the whole-cycle patterns of mortality follow a logistic law for
17 52 countries. A universal linear law is found between the ICU time in the early stage
18 and the most important quantity regarding the epidemic: its duration. Saturation
19 mortality is found to have a power law relationship with median age and bed occupancy,
20 which quantitatively explains the great variation in mortality based on the two key
21 thresholds of median age (=38) and bed occupancy (=15%). We predict that deaths will
22 be reduced by 36% when the number of beds is doubled for countries with older
23 populations. Facing the next wave of the epidemic, this model can make early
24 predictions on the epidemic duration and medical supply reservation.

25


26 Since COVID-19 was declared a pandemic by the World Health Organization (WHO)
27 on March 11, 2020, approximately 5 million deaths have been reported across 184
28 countries or regions as of October 1, 2021. Therefore, lessons learned from the first
29 wave, such as quantitative assessment of the severity of the epidemic and clarification
30 of the determining medical and social factors, are urgently needed to help policy-
31 makers prevent more deaths in the next wave. Reliable death statistics and quantitative
32 modelling are essential for understanding the pandemic¹. However, it is a great
33 challenge to quantitatively interpret observational data presenting a high variation in
34 mortality evolution across countries, which reaches two to three orders of magnitude
35 for the difference in case fatality rate (deaths per confirmed case) and crude death rate
36 (deaths per 100,000 population). We attempt to propose a reliable understanding of this
37 observation.

38

39 Previous studies have not yet reached a conclusion regarding this issue because they
40 focused only on the individual scale or the national scale and ignored the cross-scale
41 correlation. Specifically, patient-level studies have shown that older patients, men and
42 patients with underlying diseases have a greater risk of death and require respiratory
43 assistance in the intensive care unit (ICU)²⁻⁷. However, the demographics of confirmed
44 cases are changing over time, with more young people being infected in the later stages
45 than in the early stages of the outbreak. On the other hand, country-level studies have
46 suggested that healthcare resource availability, infection scale, etc., are associated with
47 mortality⁸⁻¹¹. However, countries' capacity to prevent, detect, and respond to the
48 outbreak varies widely over time¹², so COVID-19 mortality presents great
49 heterogeneity in space (across countries) and time¹³. Therefore, the commonly used
50 method of a cross-sectional study, in which the mortality data for a given day are
51 selected, yields misleading representation by comparing the mortality data at different
52 evolutionary stages. For example, two studies concluded differently on whether there
53 was a correlation between the case fatality rate and the number of tests^{8,9}. Moreover,
54 these various factors analysed at different levels must form a coherent view to offer
55 effective guidance for fighting against the pandemic.

56

57 In sharp contrast to the above-mentioned studies, we adopt a dynamic study with a
58 complete description of the whole-cycle evolution of mortality to better uncover robust
59 features and explain the underlying mechanisms, which yields a quantitative prediction
60 about future epidemic evolution. Considering that almost all countries have already
61 experienced the first wave of the epidemic, it is time to derive a law governing the
62 dynamics of COVID-19 mortality based on the data. Here, we present a logistic model
63 that accurately describes the whole-cycle evolutionary patterns of COVID-19 mortality
64 (deaths per 100,000 population, $S(t)$) across 52 countries, quantitatively explaining
65 the great variation in mortality based on two key thresholds from exact scales of the
66 median age (=38) and bed occupancy (=15%), finding the cross-scale correlations
67 between ICU time and epidemic duration with a dimensionless coefficient k . As a result,
68 cross-scale correlation analysis between individual and national scales is achieved in
69 the first wave of COVID-19 mortality (see **Fig. 1**).



71 **Fig. 1 The cross-scale correlation between the individual scale and the national**
72 **scale in this paper.**

73

74 Specifically, the data show that, for all countries, the temporal evolution of mortality
75 during the first pandemic wave well fits a logistic pattern with just two parameters (see

76 “Methods” for details), which allows decoupling the complex evolutionary behaviour
77 into two independent processes with close medical and social correspondences. One is
78 saturation mortality (s_0) in the late stage of the epidemic, which is positively correlated
79 with the state’s median age and bed occupancy (see **Fig. 2**). This finding allows us to
80 derive, from data, a law that yields a prediction of practical interest, namely, how many
81 medical supplies need to be reserved in the continuing fight against the next wave of
82 the epidemic if the aim is to cut the number of deaths by half (see **Fig. 4**). The other is
83 a characteristic survival time (τ), which is closely related to the ICU time in the early
84 stage and shows a universal linear correlation with epidemic duration across different
85 countries (see **Fig. 3**). If this is further confirmed, it would be possible to predict the
86 epidemic duration from collected data at the early stage of the outbreak (see **Table. 1**).
87 Thus, we highly recommend testing the current model, which, if successful, would
88 greatly enhance our ability to understand and control the current epidemic.

89

90 **Results**

91 **Two key thresholds associated with age, beds, and saturation mortality (s_0)**

92 When the epidemic ends, the mortality $S(t)$ evolves to s_0 , so the saturation mortality
93 parameter s_0 quantifies the epidemic. Previous published cross-sectional studies did
94 show a correlation between age, hospital beds, and mortality, but it is not clear which
95 role these factors play in different countries and at different stages of the outbreak. In
96 **Fig. 2**, we plot s_0 as a function of the nation’s median age and available hospital beds,
97 which immediately reveals some remarkable features. First, the high-mortality patterns
98 ($s_0 > \overline{s_0} = 12.0$) were all found in countries with a median age over 38 years old, which
99 suggests that median age is one of the key factors influencing mortality, consistent with
100 previous studies³⁻⁷. The current finding is more quantitative: it presents a scaling
101 between the saturation mortality and median age, with a power law exponent of 2.1 (see
102 **Fig. 2a**).

103

104 On the other hand, the deviation from this scaling is quite substantial for countries of

105 high median age (most pink dots are outside of the confidence interval, see **Fig. 2a**).
106 The strong scattering suggests that there must be other important factors causing high
107 mortality. Indeed, we found that there exists a nice scaling between saturation mortality
108 and bed occupancy at the peak of the first wave (confirmed cases at peak time over bed
109 number, see “Methods” for details) for countries with a median population age above
110 38 years old (see **Fig. 2b**). The saturation mortality increases with the peak bed
111 occupancy, following a power law of exponent 0.6, which attributes the large variation
112 in the mortality of older countries to the great variation in peak bed occupancy (almost
113 by two orders of magnitude) across countries.

114

115 For example, Wuhan City (Hubei Province, China) is comparable in population size
116 and pandemic scale to some countries. The bed occupancy (at the peak) based on the
117 number of beds before the outbreak was 39.2%, and the saturation mortality (s_0) was
118 predicted to be 24.8. However, after the construction of Fang Cang Hospital, the
119 number of beds increased by 15,000¹⁴, and s_0 reduced to 22.6, which is very close to
120 the actual saturation mortality of 22.0. Thus, the power law could explain 76.7% (248
121 deaths) of the decline in the number of deaths, as shown in **Fig. 4b**.


122

123 The peak bed occupancy reflects the degree of countries’ medical support during the
124 pandemic. It would be interesting to discover a critical value of the peak bed occupancy
125 to separate low and high mortality. Shown in **Fig. 2b**, a value between 10% to 20%,
126 e.g., 15%, may be a reference. It would be intriguing to examine the second wave of
127 data to determine whether a universal threshold can be found.

128

129 In summary, the high variation in mortality across countries can be explained
130 quantitatively. First, two key quantities of median age and bed occupancy can classify
131 all countries into three typical patterns (see **Fig. 2c**). Older countries (>38) with high
132 bed occupancy (>15%) have far greater mortality than the other two low-mortality
133 groups, which include younger groups (<38), without exception, and the group with
134 low bed occupancy (abundant medical supplies). What is interesting is that some older

135 countries (>38) can evolve into a low-mortality pattern if they have a low bed
 136 occupancy ($<15\%$). This indicates that bed occupancy is an essential indicator to
 137 evaluate the effectiveness of national anti-COVID-19 measures.



1:
 139 **Fig. 2 The great mortality variation is explained by the median age and bed**
 140 **occupancy. a** The scaling between saturation mortality and the median age for all
 141 countries ($N = 52$). **b** The scaling between saturation mortality and peak bed

142 occupancy for countries aged over 38 years old ($N = 24$). **a** and **b** take the double
143 logarithmic coordinates for a better display of the data. The orange, blue and pink dots
144 correspond to the low-mortality pattern-1, low-mortality pattern-2, and high-mortality
145 pattern, respectively. The black lines are the fitting predictions by power functions. The
146 grey areas are the 95% confidence intervals. Note that the red circle furthest from the
147 confidence interval in **Fig. 2b** represents Belgium, probably because it uses a broader
148 inclusion criterion for COVID-19 deaths¹⁵. **c** The flow of COVID-19 mortality patterns
149 between the region, median age, and bed occupancy. The orange, blue and pink
150 connecting lines correspond to the low-mortality pattern-1, low-mortality pattern-2, and
151 high-mortality pattern, respectively. The width of each line is proportional to the
152 number of countries.


153

154 **The dimensionless coefficient k between ICU time and epidemic duration**

155 The present two-parameter model not only explained the large variations in mortality
156 across countries but also discovered a cross-scale correlation between ICU time and
157 epidemic duration, which provides new insights regarding the spread and evolution of
158 COVID-19. First, a dimensionless coefficient k can be derived from our model (see
159 “Methods” for details), which is the ratio of the epidemic duration to the model
160 parameter τ (which coincides with the ICU time of non-survivors in the early stage of
161 the epidemic). Importantly, we find that the k values are nearly constant across
162 different continents, and the average is 7.0 (IQR, 6.3-7.7), as shown in **Fig. 3**. This
163 linear law is better obeyed for countries with shorter ICU times ($\tau < 20$), while the data
164 are more diffused for countries with longer ICU times ($\tau > 20$) (see **Fig. 3a**). This
165 suggests that ICU time is a good indicator of the “strength” of the epidemic, or how
166 long it may last. The longer the ICU time is, the longer the epidemic will last. Note that
167 the ICU time is related to an individual’s antiviral ability, while the duration of the
168 epidemic is a social scale property. Thus, this linear law reveals an important property
169 of COVID-19, which might be very important and needs further investigation.
170 Knowing the value of k , one may then predict the duration of the outbreak from the
171 data of the ICU time (τ) in the early stage. It would be intriguing to test this finding

172 with data and make predictions for the duration of the second wave.

173



174

175 **Fig. 3 The cross-scale correlation between τ (ICU time) and epidemic duration.**

176 **a-e** are the correlations with different but similar correlation coefficients k for all

177 countries, Europe, Africa, Asia, and America, respectively. The abscissa variable is the

178 model fitting parameter τ , which represents the ICU time of non-survivors in the early

179 stage of the epidemic. The ordinate variable is the duration of the epidemic. The blue

180 dots are the data across countries. The black lines are the fitting predictions by linear

181 functions. The grey areas are the 95% confidence intervals.

182

183 **Quantitative evaluation of national interventions and the prediction of epidemic**

184 **duration**

185 The above discussion on the cross-scale correlations in the first wave of COVID-19

186 mortality yields a method for the quantitative evaluation of the efficacy of interventions


187 and the prediction of epidemic duration. First, a good fit is shown with the scaling

188 between bed occupancy and saturation mortality (see **Fig. 2b**) for countries with low

189 mortality, such as Austria ($s_0 = 7.02$) and Germany ($s_0 = 9.95$), and for countries with
 190 high mortality, such as Canada ($s_0 = 22.85$) and Sweden ($s_0 = 54.54$). Interestingly,
 191 this power law predicts that the deaths will be reduced by approximately 36% when the
 192 number of beds is doubled (see **Fig. 4a**). In other words, increasing the number of beds
 193 is very effective for preventing deaths in older countries. Specifically, if Canada could
 194 double the number of beds, approximately 3,500 deaths could be prevented in the first
 195 wave, and similarly, approximately 2,200 deaths could be prevented for Sweden, as
 196 shown in **Fig. 4a**.

197

198 The other remarkable prediction of the present model is the duration of the whole
 199 epidemic by using the dimensionless coefficient k and the ICU time in the early stage
 200 of the outbreak. As shown in Table 1, the durations predicted by using a range of $k =$
 201 $7 - 8$ and the reported ICU time are very close to the actual values. As a result,
 202 policymakers can more accurately anticipate the difficulties of the fight against the
 203 pandemic and better optimize the load on the health system to minimize the number of
 204 deaths.



205

206 **Fig. 4 Changes in mortality as bed numbers increase. a** Reduction in saturation
 207 mortality when changing the number of beds. The black and orange lines represent
 208 Sweden and Canada, respectively. **b** Contribution of the construction of Fang Cang

209 hospital to the reduction in mortality in Wuhan City (Hubei Province, China). The grey
210 circles are the official reported data. The red line represents the simulation of mortality
211 evolution without Fang Cang hospital, while the blue line represents the simulation of
212 mortality evolution with Fang Cang hospital.

213

214 **Table 1. The prediction of epidemic duration by using the $k = 7 - 8$**

Country/Region	ICU time* (days)	Actual duration (days)	Predicted duration (days)
Wuhan	7	51	49-56
Germany	9	73	63-72
Italy	10	87	70-80

215 * Data are expressed as the median in references¹⁶⁻¹⁸.

216

217 **Discussion**

218 The COVID-19 pandemic has forced us to rethink the way countries prepare for public
219 health crises. Although the end of the crisis is not nearly in sight yet, it is time to learn
220 lessons from the first wave to improve the global capacity to respond to health crises of
221 this magnitude. This becomes possible since, for the first time in the history of science,
222 so much information has been collected and shared worldwide, which makes it possible
223 to gain a deeper understanding of epidemic evolution¹⁹.

224

225 The present study demonstrates the validity of a logistic model to describe the whole-
226 cycle evolution of COVID-19 mortality in the first wave across 52 countries. We then
227 find, from the data, a remarkable correlation for epidemic characteristics between the
228 individual scale (age and ICU time) and national scale (mortality and epidemic
229 duration). This correlation quantitatively answers two crucial questions of major
230 interest, namely, why does COVID-19 mortality vary so widely from country to country,
231 and how long will the epidemic last?

232

233 For the first question, the power law correlation between the median age, bed occupancy,
234 and saturation mortality yield a quantitative explanation for the large observed variation
235 in mortality across countries (see **Fig. 2**), with two key thresholds, 38 years old for
236 median age and 15% for bed occupancy, which classifies countries into three typical
237 patterns (see **Fig. 2c**). Specifically, countries that are older could flatten the mortality
238 curve by reducing bed occupancy to under 15%, offering an impressive model for other
239 countries in reducing deaths in the next wave.

240

241 For the second question, the linear law between the two different time scales makes it
242 possible to predict the duration of the whole epidemic wave by using the ICU time in
243 the early stage (see **Fig. 3, Table 1**). It is well known that the long-term forecasting of
244 outbreaks is a great challenge since there are unpredictable and complex factors that
245 can influence epidemic evolution. Indeed, we also found that some countries with
246 longer epidemic duration had greater fluctuations of the slope in the linear law, probably
247 because these countries were more likely to experience those unexpected factors (see
248 **Fig. 3**). Even so, on the national scale, there is still a nearly universal linear law across
249 countries, which suggests that the temporal cross-scale association is an important
250 feature of the COVID-19 pandemic. An interesting future topic is to verify and compare
251 the values of the dimensionless coefficient k with the values in other epidemics, such
252 as SARS or the annual flu, which may bring new insights into understanding the spread
253 and evolution of the epidemic.

254

255 An important finding of the present study is the importance of the ICU time of non-
256 survivors in the early stage, which is often overlooked in clinical studies. We found that
257 Wuhan City had the smallest τ (6.3 days) among all the regions included in the study,
258 which was very close to the 7 days of the clinical study¹⁶ (see **Fig. 7**). This result is
259 consistent with the fact that Wuhan City was the first outbreak point and that the
260 community knew little about the virus at the beginning of COVID-19. Moreover, the
261 wide range of τ (ICU time) across countries (see **Fig. 3**) needs to be studied and
262 explained in the future, and the current findings suggest collecting more accurate ICU

263 time data for better prediction of the next wave of the pandemic.

264

265 Our study also has several limitations. First, the data analysed here are from public
266 databases. The limited quality, different statistical standards, and incompleteness of
267 databases may affect the precision of our description. Second, our study does not
268 include countries with complex evolutionary behaviours, such as repeated rebounding
269 of the outbreak. Third, we used median age data at the national level instead of at the
270 patient level, as such data are currently lacking in most countries. Finally, we use the
271 number of beds before the outbreak instead of the actual data that tend to increase
272 during the epidemic, which are currently difficult to obtain. Although these factors
273 influence the precision of the description, they would not affect the main conclusions
274 of the study for the first wave of COVID-19 in most countries.

275


276 In conclusion, we present dynamic modelling to decouple the complex evolution of
277 COVID-19 mortality into two key processes: the ICU duration of non-survivors in the
278 early stage and the saturation mortality in the late stage. This analysis uncovers three
279 cross-correlations between the individual scale and the national scale in COVID-19
280 mortality, which enables us to evaluate interventions quantitatively and predict the
281 epidemic duration. This framework also has other potential applications, such as
282 providing country-specific suggestions for the reservation of medical supplies to fight
283 against the next wave of COVID-19 so that more deaths can be prevented.

284

285 **Methods**

286 **Study design.** As of October 1, 2021, 184 countries or regions had reported COVID-
287 19 deaths. Due to technical limitations, government interventions and multiple
288 corrections of the data, the mortality evolution in some countries shows complex
289 behaviours. For example, in **70** countries, the second wave breaks out before the first
290 wave of the epidemic ends. Since the goal of this study is to analyse the whole evolution
291 of mortality in the first wave, we propose the explicit inclusion criterion that only

292 countries with post-peak daily deaths falling to less than one-tenth of the peak should
293 be considered a qualified sample. Considering the statistical stability, qualified samples
294 should have a cumulative number of deaths of more than 100 cases. Finally, 52
295 countries or regions were included in this study (see **Fig. 5**).



296

297 **Fig. 5 The inclusion criteria in this paper.**

298

299 **Data and Metrics.** The data used in our study all come from open-access databases.
300 Specifically, the COVID-19 case data are aggregated from the Johns Hopkins
301 University database²⁰ (as of October 1, 2021), while the data of Wuhan are from the
302 Health Commission of Hubei Province²¹. The population, median age, and hospital
303 beds (per 1,000 population) are from the database of Our World in Data²². For China,
304 we chose the data of Wuhan City (Hubei Province, China) instead of national data
305 because of Wuhan's comparable population size and pandemic scale. The population

306 and bed data in Wuhan are from the Wuhan Statistics Bureau²³. It is worth mentioning
307 that the data of these state-level variables are updated to the most recent year but often
308 not to the same year.


309

310 **Bed occupancy.** We propose the “**bed occupancy**” to evaluate the availability of
311 medical resources across countries, which is calculated by dividing the number of
312 hospitalized cases by the number of beds at the peak of the epidemic. Here, “the number
313 of hospitalized cases” is calculated by the following relation: hospitalized cases =
314 confirmed – recovered - deaths.

315

316 **The epidemic duration.** The epidemic duration is defined to prevent the long-tail effect
317 when comparing and analysing the evolutionary time of the epidemic across countries.
318 Using the peak of daily new deaths as a reference, we define the date when the new
319 deaths climb to more than one-tenth of the peak as the outbreak date ($t_{outbreak}$) and the
320 date when the new deaths fall below one-tenth of the peak as the saturation date
321 ($t_{saturation}$) (see **Fig. 6a**). The time between the outbreak date and the saturation date
322 is the duration of the epidemic (see **Fig. 6b**). A 10-day smoothing is carried out on the
323 daily new deaths due to the large fluctuations.

324



325

326 **Fig. 6 The epidemic duration of the first wave (ex. Switzerland).** a The daily new
327 deaths and the characteristic date. The black circles are the reported daily new deaths.

328 The blue line is the 10-day smoothing of the daily deaths. The square is the peak of
 329 daily new deaths. The regular triangle is the outbreak date when the new deaths climb
 330 to more than one-tenth of the peak. The inverted triangle is the saturation date when the
 331 new deaths fall below one-tenth of the peak. **b** The cumulative deaths and the duration
 332 of the first wave. The black circles are the reported cumulative deaths. The red circles
 333 are the data for the duration of the first wave.

334

335 **Model and parameters.** In the early stages of the outbreak, the number of deaths
 336 increased almost exponentially due to weak intervention. With the expansion of the
 337 death toll, the social system takes actions to slow down the growth of mortality, such
 338 as increasing available medical resources, controlling the spread of the epidemic, and
 339 protecting high-risk groups. Eventually, the death toll tends to be saturated in the late
 340 stages of the epidemic. Therefore, we use the logistic model to fit the COVID-19
 341 mortality (deaths per 100,000 population, $S(t)$):

$$342 \quad \frac{dS(t)}{dt} = \frac{1}{\tau} S(t) \left(1 - \frac{S(t)}{s_0} \right) \quad (1)$$

343 The solution to equation (1) can be written as:

$$344 \quad S(t) = \frac{s_0}{1 + e^{t_c - t/\tau}} \quad (2)$$

345

346 s_0 When $t \gg 0$, $S(t) \approx s_0$. Therefore, s_0 denotes the saturation mortality in the
 347 late stage of the epidemic.


348

349 t_c When $t = t_c$, $S(t) = s_0/2$. Therefore, t_c denotes the characteristic time when
 350 mortality reaches half of the saturation mortality.

351

352 τ When $t \approx 0$, $S(t) \ll s_0$, equation (1) can be written as $\tau^{-1} \approx S(t)'/S(t)$.
 353 Therefore, τ^{-1} denotes the exponential growth rate of mortality, while τ is the
 354 characteristic time for new deaths in the early stage of the epidemic. Since almost all
 355 reported deaths of COVID-19 occur in ICU, we propose that τ denotes the time in

356 ICU of the non-survivors in the early stage, which is well validated by published clinical
 357 data¹⁶⁻¹⁸ (see **Fig. 7**).
 358



359
 360 **Fig. 7 ICU time and the value of τ .** The 45-degree black line indicates the equality of
 361 the observed and predicted data.

362

363 **The dimensionless coefficient k**

364 When $t = t_{outbreak}$ or $t = t_{saturation}$, equation (2) can be written as:

365
$$t_{outbreak} = t_c - \ln\left(\frac{S_0}{S(t_{outbreak})} - 1\right) * \tau \quad (3.1)$$

366
$$t_{saturation} = t_c - \ln\left(\frac{S_0}{S(t_{saturation})} - 1\right) * \tau \quad (3.2)$$


367 Then, the duration can be obtained by subtracting the two equations above:

368
$$duration = t_{saturation} - t_{outbreak} = k * \tau \quad (4)$$

369 Here, k is:

370
$$k = \ln\left(\frac{\frac{S_0}{S(t_{outbreak})} - 1}{\frac{S_0}{S(t_{saturation})} - 1}\right) \quad (5)$$

371 Thus, we can see that the duration is strictly linearly related to τ by the factor k . The
 372 values of k across countries are shown in **Fig. 8**. We can see that most countries have
 373 k values between 7 and 8, although their mortality and τ values vary widely.




375


376 **Fig. 8 The k values of 52 countries. a-d** are the k values for countries in Europe,
 377 Africa, Asia, and America, respectively. The blue dots are the data across countries.
 378 The black dashed lines are the average of countries by continent. The grey areas are the
 379 interquartile range (25th–75th).

380

381 We use equation (2) to fit the mortality data of 52 countries in the first wave of COVID-
 382 19 (see **Fig. 9**) and obtain the values of the model parameters s_0 and τ .

383





386 **Fig. 9** Fitting of mortality using a logistic model. The red point is the officially reported
 387 data, and the black line is the fitting result with 95% confidence intervals (blue bands).

388 **References**

- 389 1 Viglione, G. The true toll of the pandemic. *Nature* **585**, 22–24,
390 doi:10.1038/d41586-020-02497-w (2020).
- 391 2 Wu, Z. Y. & McGoogan, J. M. Characteristics of and Important
392 Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in
393 China Summary of a Report of 72 314 Cases From the Chinese Center
394 for Disease Control and Prevention. *Jama-Journal of the American
395 Medical Association* **323**, 1239–1242, doi:10.1001/jama.2020.2648
396 (2020).
- 397 3 Chen, T. *et al.* Clinical characteristics of 113 deceased patients
398 with coronavirus disease 2019: retrospective study. *BMJ-British
399 Medical Journal* **368**, 12, doi:10.1136/bmj.m1091 (2020).
- 400 4 Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized
401 Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan,
402 China. *Jama-Journal of the American Medical Association* **323**,
403 1061–1069, doi:10.1001/jama.2020.1585 (2020).
- 404 5 Perez-Saez, J. *et al.* Serology-informed estimates of SARS-CoV-2
405 infection fatality risk in Geneva, Switzerland. *The Lancet.
406 Infectious diseases*, doi:10.1016/s1473-3099(20)30584-3 (2020).
- 407 6 Sudharsanan, N., Didzun, O., Barnighausen, T. & Geldsetzer, P.
408 The Contribution of the Age Distribution of Cases to COVID-19
409 Case Fatality Across Countries: A 9-Country Demographic Study.
410 *Annals of internal medicine*, doi:10.7326/m20-2973 (2020).
- 411 7 Mallapaty, S. The coronavirus is most deadly if you are old and
412 male. *Nature* **585**, 16–17, doi:10.1038/d41586-020-02483-2 (2020).
- 413 8 Liang, L.-L., Tseng, C.-H., Ho, H. J. & Wu, C.-Y. Covid-19
414 mortality is negatively associated with test number and
415 government effectiveness. *Scientific Reports* **10**,
416 doi:10.1038/s41598-020-68862-x (2020).
- 417 9 Sorci, G., Faivre, B. & Morand, S. Explaining among-country
418 variation in COVID-19 case fatality rate. *Scientific Reports* **10**,
419 doi:10.1038/s41598-020-75848-2 (2020).
- 420 10 Khan, J. R., Awan, N., Islam, M. M. & Muurlink, O. Healthcare
421 Capacity, Health Expenditure, and Civil Society as Predictors of
422 COVID-19 Case Fatalities: A Global Analysis. *Frontiers in Public
423 Health* **8**, doi:10.3389/fpubh.2020.00347 (2020).
- 424 11 Ji, Y., Ma, Z., Peppelenbosch, M. P. & Pan, Q. Potential
425 association between COVID-19 mortality and healthcare resource
426 availability. *Lancet Global Health* **8**, E480–E480,
427 doi:10.1016/s2214-109x(20)30068-1 (2020).
- 428 12 Kandel, N., Chungong, S., Omaar, A. & Xing, J. Health security
429 capacities in the context of COVID-19 outbreak: an analysis of

- 430 International Health Regulations annual report data from 182
431 countries. *Lancet* **395**, 1047–1053, doi:10.1016/s0140-
432 6736(20)30553-5 (2020).
- 433 13 Sen, P., Yamana, T. K., Kandula, S., Galanti, M. & Shaman, J.
434 Burden and characteristics of COVID-19 in the United States
435 during 2020. *Nature* **598**, 338–341, doi:10.1038/s41586-021-03914-
436 4 (2021).
- 437 14 The Joint Prevention and Control Mechanism of the State Council.
438 *Press Conference*,
439 <<http://www.gov.cn/xinwen/gwylflkjz123/index.htm>> (2020).
- 440 15 Sierra, N. B., Bossuyt, N., Braeye, T., Leroy, M. & Renard, F.
441 All-cause mortality supports the COVID-19 mortality in Belgium
442 and comparison with major fatal events of the last century.
443 *Archives of Public Health* **78** (2020).
- 444 16 Xie, J. *et al.* Clinical characteristics and outcomes of
445 critically ill patients with novel coronavirus infectious
446 disease (COVID-19) in China: a retrospective multicenter study.
447 *Intensive Care Medicine* **46**, 1863–1872, doi:10.1007/s00134-020-
448 06211-2 (2020).
- 449 17 Herrmann, J. *et al.* COVID-19 Induced Acute Respiratory Distress
450 Syndrome—A Multicenter Observational Study. *Frontiers in*
451 *Medicine* **7**, doi:10.3389/fmed.2020.599533 (2020).
- 452 18 Grasselli, G., Greco, M., Zanella, A., Albano, G. & Cecconi, M.
453 Risk Factors Associated with Mortality among Patients with COVID-
454 19 in Intensive Care Units in Lombardy, Italy. *JAMA Internal*
455 *Medicine* (2020).
- 456 19 Preparing for the next pandemic. *Nat. Med.* **27**, 357–357,
457 doi:10.1038/s41591-021-01291-z (2021).
- 458 20 Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard
459 to track COVID-19 in real time. *Lancet Infectious Diseases* **20**,
460 533–534, doi:10.1016/s1473-3099(20)30120-1 (2020).
- 461 21 Health Commission of Hubei Province. *Preventing and controlling*
462 *SARS-CoV-2 pneumonia outbreaks*, <<https://wjw.hubei.gov.cn/>>
463 (2020).
- 464 22 Roser, M., Ritchie, H., Ortiz-Ospina, E. & Hasell, J. Coronavirus
465 Pandemic (COVID-19). *Our World in Data* (2020).
- 466 23 Wuhan Municipal Statistics Bureau & State Statistical Bureau
467 Wuhan Investigation Team. *Wuhan Statistical Yearbook 2020*. Vol.
468 32 (China Statistics Press, 2020).
- 469

470 **Author information**

471 **Affiliations**

472 **Institute of Health System Engineering, College of Engineering, Peking**
473 **University, Beijing, China.**

474 Lei Zhang, Yu-Rong She, Guang-Hui She, Rong Li and Zhen-Su She
475 **State Key Laboratory for Turbulence and Complex Systems, Peking University,**
476 **Beijing, China.**

477 Rong Li and Zhen-Su She

478

479 **Author contributions**

480 Z.S.S. and R.L. designed the study and revised the manuscript. L. Z. built the model,
481 analysed the result, and wrote the manuscript. Y.R.S. and G.H.S collected data and
482 contributed to the statistical analyses. All authors have approved the submitted version.

483 **Corresponding author**

484 Correspondence to Zhen-Su She(she@pku.edu.cn) & Rong Li([rongli-](mailto:rongli-coe@pku.edu.cn)
485 [coe@pku.edu.cn](mailto:rongli-coe@pku.edu.cn));

486

487 **Competing interests**

488 The authors declare no competing interests.

489

490 **Legends**

491 **Fig. 1 The cross-scale correlation between the individual scale and the national**
492 **scale in this paper.**

493 **Fig. 2 The great mortality variation is explained by the median age and bed**
494 **occupancy. a** The scaling between saturation mortality and the median age for all
495 countries ($N = 52$). **b** The scaling between saturation mortality and peak bed
496 occupancy for countries aged over 38 years old ($N = 24$). **a** and **b** take the double
497 logarithmic coordinates for a better display of the data. The orange, blue and pink dots

498 correspond to the low-mortality pattern-1, low-mortality pattern-2, and high-mortality
499 pattern, respectively. The black lines are the fitting predictions by power functions. The
500 grey areas are the 95% confidence intervals. Note that the red circle furthest from the
501 confidence interval in **Fig. 2b** represents Belgium, probably because it uses a broader
502 inclusion criterion for COVID-19 deaths¹⁵. **c** The flow of COVID-19 mortality patterns
503 between the region, median age, and bed occupancy. The orange, blue and pink
504 connecting lines correspond to the low-mortality pattern-1, low-mortality pattern-2, and
505 high-mortality pattern, respectively. The width of each line is proportional to the
506 number of countries.

507 **Fig. 3 The cross-scale correlation between τ (ICU time) and epidemic duration.**
508 **a-e** are the correlations with different but similar correlation coefficients k for all
509 countries, Europe, Africa, Asia, and America, respectively. The abscissa variable is the
510 model fitting parameter τ , which represents the ICU time of non-survivors in the early
511 stage of the epidemic. The ordinate variable is the duration of the epidemic. The blue
512 dots are the data across countries. The black lines are the fitting predictions by linear
513 functions. The grey areas are the 95% confidence intervals.

514 **Fig. 4 Changes in mortality as bed numbers increase. a** Reduction in saturation
515 mortality when changing the number of beds. The black and orange lines represent
516 Sweden and Canada, respectively. **b** Contribution of the construction of Fang Cang
517 hospital to the reduction in mortality in Wuhan City (Hubei Province, China). The grey
518 circles are the official reported data. The red line represents the simulation of mortality
519 evolution without Fang Cang hospital, while the blue line represents the simulation of
520 mortality evolution with Fang Cang hospital.

521 **Fig. 5 The inclusion criteria in this paper.**

522 **Fig. 6 The epidemic duration of the first wave (ex. Switzerland). a** The daily new
523 deaths and the characteristic date. The black circles are the reported daily new deaths.
524 The blue line is the 10-day smoothing of the daily deaths. The square is the peak of
525 daily new deaths. The regular triangle is the outbreak date when the new deaths climb

526 to more than one-tenth of the peak. The inverted triangle is the saturation date when the
527 new deaths fall below one-tenth of the peak. **b** The cumulative deaths and the duration
528 of the first wave. The black circles are the reported cumulative deaths. The red circles
529 are the data for the duration of the first wave.

530 **Fig. 7 ICU time and the value of τ .** The 45-degree black line indicates the equality of
531 the observed and predicted data.

532 **Fig. 8 The k values of 52 countries. a-d** are the k values for countries in Europe,
533 Africa, Asia, and America, respectively. The blue dots are the data across countries.
534 The black dashed lines are the average of countries by continent. The grey areas are the
535 interquartile range (25th–75th).

536 **Fig. 9 Fitting of mortality using a logistic model.** The red point is the officially reported
537 data, and the black line is the fitting result with 95% confidence intervals (blue bands).

538

539 **Table 1. The prediction of epidemic duration by using the $k = 7 - 8$**